IDIBELL on the media
IDIBELL receives FORTALECE grant from the Carlos III Health Institute
The grant, of €2,500,000, will promote the Smart Health Community project
Scientists find how to define targeted therapies in lung cancer thanks to a genetic sequencing platform
The use of this massive genetic sequencing platform could improve patient survival thanks to the detection of therapeutic targets and mutations that predispose to cancer.
Scientists discover potential biomarkers for male infertility: the composition of microRNAs and their isoforms
A study led by Dr. Sara Larriba’s team at IDIBELL, in collaboration with Fundació Puigvert and IGTP, demonstrates that the concentration of microRNAs and their isoforms in semen samples may reflect alterations in sperm production.
Artificial intelligence helps take decisions about bone marrow transplant
Researchers from IDIBELL and ICO have used computational models to analyze bone marrow transplant data from 33,927 patients and develop a tool that provides personalized estimates of mortality from this type of therapies.
Scientists open up a new way to fight cancer through the MYC gene
A team of international researchers has identified the specific processes by which the MYC oncogene promotes this disease and, this way, demonstrated that this gene can attack specific weaknesses in tumor cells.
IDIBELL and Bellvitge Hospital take the first step towards personalized medicine in kidney transplantation
The research group has managed to demonstrate the good results of an algorithm that adjusts the doses of the immunosuppressant tacrolimus according to the characteristics of each person. The results have been published in the scientific journal Kidney International.
Scientists create a mouse model to study the progression of a type of leukemia and look for more effective treatments
The model has been created by injecting tumor cells from a patient into a mouse to mimic the transformation of leukemia into a more aggressive form, making it possible to learn about the real evolution of the disease and be able to test new treatments.
IDIBELL receives 25.907€ thanks to the donations of Bonpreu and Esclat customers
In November, Bonpreu and Esclat clients made 185.804 donations that have made it possible to obtain 25.907€ for IDIBELL to develop new therapies for diabetes through the Solidarity Roundup, a tool developed by Worldcoo.
